Search Results
Month: November 2025
Q2 Quick Note #03: Early Trial Results for Bexicaserin in DEE
A phase 1b and 2a clinical trial tested bexicaserin in people with severe epilepsies and found early signs that the medication may help reduce seizure activity. Researchers report that the treatment was generally well tolerated, supporting continued study in future trials.
Q2 Quick Notes: Breaking down the latest in KCNQ2 research
KCNQ2 DEE: Lived Experiences and Outcomes1 Dr. Michele Postashman’s newly published article in Epilepsy & Behavior details a qualitative, lived experience study of individuals and families affected by KCNQ2-DEE. With recruitment help from KCNQ2 Cure Alliance (thank you to those who participated!), they interviewed 53 parents of people with the disorder. Findings show that non-seizure…
Q2 Quick Note #02: Genetic Findings in a Turkish DEE Cohort
Researchers in Turkey used gene panels and whole exome sequencing to study the causes of developmental and epileptic encephalopathies, identifying KCNQ2 as one of the most frequently involved genes. The findings highlight the importance of early genetic testing for accurate diagnosis and care planning.
Q2 Quick Note #01: Lived Experiences of Families Affected by KCNQ2-DEE
A new study involving 53 parents of children with KCNQ2-DEE highlights that communication challenges, cognitive delays, and daily living needs are often more burdensome than seizures. These insights help guide future treatments that focus on quality of life, not just seizure reduction.